Colorectal cancer Cancer
Conditions
Interventions
Pseudonymous digital images of histological slides generated as part of routine NHS care will be obtained with participant consent. Images will then be run through three different machine learning alg
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Clinical suspicion or confirmed diagnosis of colorectal adenocarcinoma of any stage 2.1. Participant is scheduled for anti-cancer treatment including one or more of the: 2.1.1. Resection of primary tumour or metastatic disease 2.1.2. Systemic anti-cancer therapy including chemotherapy, biological therapy or immunotherapy in either the neoadjuvant, adjuvant or metastatic settings 2.1.3. Local radiotherapy or Stereotactic Ablative Radiotherapy (SABR) tumour ablative therapies 3. The patient is scheduled for palliative care only 4. Age >18 years 5. The participant is willing to comply with all study requirements
Exclusion criteria
Exclusion criteria: 1. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial. 2. Treatment with chemoradiotherapy prior to diagnostic biopsy related to the cancer under study in the past 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of integrating machine learning algorithms into the digital pathology and clinical decision pathway for CRC will be measured using questionnaire data obtained from clinical care and pathologist teams after a decision on real-world treatment has been made | — |
Secondary
| Measure | Time frame |
|---|---|
| Conclusions on whether algorithm analyses would have changed real-world treatment recommendations will be derived from percentage changes of theoretical treatment recommendations captured from questionnaires completed by clinical care and pathologist teams at the end of the study | — |
Countries
England, United Kingdom
Contacts
Public ContactChen-Chun Pai
Outcome results
None listed